Calcium Metabolism in Premenopausal Women Treated by a Gn-RH Agonist for Uterine Myoma.
article
OA: bronze
CC0
⤵ 1 in-corpus citation
Abstract
Eleven premenopausal women with uterine myoma who received 300 micrograms of intranasal Gn-RH agonist (buserelin) three times daily for 6 months participated in this study. Serum estradiol, some parameters related to calcium metabolism and bone mineral density of the lumbar vertebrae assessed by quantitative computerized tomography were evaluated prior to, at the end of and 3 months after the treatment. Hypo-estrogenism was sustained during the treatment period. Calcitonin levels decreased rapidly after the first 2 weeks of the treatment and the fasting urinary hydroxyproline to creatinine excretion value increased in 1 month. Both serum alkaline phosphatase and osteocalcin increased slightly during the treatment. The serum m-parathyroid hormone levels showed no significant changes. There was no significant reduction in the mean lumbar vertebral bone mineral content (BMC) at the end of the treatment, but 4 out of 11 cases showed a decrease in BMC, which returned to the pretreatment level in 3 months after the cessation of treatment. From these findings, this therapy appears to have some effects on calcium metabolism during medication, but no adverse ones in the 3 months after treatment.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN 1988
- Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis 1988
- Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol 1988
Cited by (1)
References (15)
- Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol via openalex
- Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis via openalex
- REVERSIBLE TRABECULAR BONE DENSITY LOSS FOLLOWING INDUCED HYPO‐OESTROGENISM WITH THE GnRH ANALOGUE BUSERELIN IN PREMENOPAUSAL WOMEN via openalex
- W2009830077 via openalex
- W2024103219 via openalex
- W2027109535 via openalex
- W2055353584 via openalex
- W263746262 via openalex
- W2081568627 via openalex
- W2095138158 via openalex
- W2129449855 via openalex
- W2297593361 via openalex
- W2055427983 via openalex
- W1561293749 via openalex
- W1978894035 via openalex
Cited by (1)
SciLite annotations
chemicals 9
calcium
buserelin
estradiol
calcium
mineral
hydroxyproline
creatinine
mineral
calcium
organisms 1
noordeloos 2009062
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0
· commercial use OK